Drug repurposing approach to fight COVID-19
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target
Y Wang, V Anirudhan, R Du, Q Cui… - Journal of medical …, 2021 - Wiley Online Library
The global pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐
CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people …
CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people …
Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19
SARS-CoV-2 is responsible for the current COVID-19 pandemic. On the basis of our
analysis of hepatitis C virus and coronavirus replication, and the molecular structures and …
analysis of hepatitis C virus and coronavirus replication, and the molecular structures and …
Sofosbuvir for previously untreated chronic hepatitis C infection
E Lawitz, A Mangia, D Wyles… - … England Journal of …, 2013 - Mass Medical Soc
Background In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a
hundred years. After examining the molecular structures and activities of hepatitis C viral …
hundred years. After examining the molecular structures and activities of hepatitis C viral …
Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19)
The viral infection caused by SARS-CoV-2 has increased the mortality rate and engaged
several adverse effects on the affected individuals. Currently available antiviral drugs have …
several adverse effects on the affected individuals. Currently available antiviral drugs have …
Nucleotide analogues as inhibitors of SARS‐CoV polymerase
Abstract SARS‐CoV‐2, a member of the coronavirus family, has caused a global public
health emergency. Based on our analysis of hepatitis C virus and coronavirus replication …
health emergency. Based on our analysis of hepatitis C virus and coronavirus replication …
Precision therapeutic targets for COVID-19
ZA Krumm, GM Lloyd, CP Francis, LH Nasif… - Virology journal, 2021 - Springer
Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS …
emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS …
A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development
Abstract Coronavirus disease 2019 (COVID-19) is a devastating viral infection caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The incidence and …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The incidence and …
Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory …
The efforts towards develo** a potential drug against the current global pandemic, COVID-
19, have increased in the past few months. Drug development strategies to target the RNA …
19, have increased in the past few months. Drug development strategies to target the RNA …